Pharsight

Igalmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497711 BIOXCEL NA
Jun, 2039

(15 years from now)

US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(15 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(15 years from now)

Igalmi is owned by Bioxcel.

Igalmi contains Dexmedetomidine Hydrochloride.

Igalmi has a total of 4 drug patents out of which 0 drug patents have expired.

Igalmi was authorised for market use on 05 April, 2022.

Igalmi is available in film;buccal, sublingual dosage forms.

Igalmi can be used as acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration.

The generics of Igalmi are possible to be released after 26 June, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic